Kinetic degradation study for the first licenced anti-influenza polymerase inhibitor, baloxavir marboxil, using HPLC-MS.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of separation science"
DOI: 10.1002/jssc.202200020
Abstract: The first licensed polymerase inhibitor, baloxavir marboxil was recently approved for the treatment of influenza A and B viruses. Furthermore, there is growing interest in testing the antiviral activity of baloxavir marboxil against Coronavirus. Despite… read more here.
Keywords: inhibitor baloxavir; degradation; polymerase inhibitor; baloxavir marboxil ... See more keywords